journal article·2020-10-01Open access

Evaluation of Hyaluronic Acid to Modulate Oral Squamous Cell Carcinoma Growth In Vitro

Jordan Ringer, Bryan Morrison, Karl Kingsley

Abstract

Introduction: Previous studies have demonstrated that glycosaminoglycan hyaluronic acid (HA) is capable of mediating oral tumor growth. Some clinical evidence has suggested reduced HA expression predicts poor cancer prognosis and that HA-chemotherapy conjugates may function synergistically to inhibit oral tumor growth. Other studies have found conflicting results that suggest enhanced CD44-HA-mediated growth and proliferation. Due to the lack of clarity regarding HA function, the primary goal of this study was to investigate the effects of HA using well-characterized oral cancer cell lines. Methods: Using several commercially available oral squamous cell carcinoma lines (and a normal non-cancerous control), 96-well growth and viability assays were conducted using HA (alone and in combination with chemotherapeutic agents paclitaxel and PD98059). Results: Different results were observed in each of the cell lines evaluated. HA induced small, non-significant changes in cellular viability among each of the cell lines within a narrow range (1–8%), p = 0.207. However, HA induced differing effects on growth, with minimal, non-significant changes among some cell lines, such as SCC4 (+1.7%), CCL-30 (−2.8%), and SCC15 (−2.5%), p = 0.211 and more robust inhibition among other cell lines, SCC9 (−24.4%), SCC25 (−36.6%), and CAL27 (−47.8%), p = 0.0001. Differing effects were also observed with growth and viability under concomitant administration of HA with PD98059 or paclitaxel. Further analysis of these data revealed strong inverse (Pearson’s) correlations between initial baseline growth rate and responsiveness to HA administration, ranging from R = −0.27 to R = −0.883. Conclusion: The results of this study revealed differing responses to HA, which may be inversely correlated with intrinsic characteristics, such as the baseline growth rate. This may suggest that the more rapidly growing cell lines are more responsive to combination therapy with hyaluronic acid; an important finding that may provide insights into the mechanisms responsible for these observations.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Proteoglycans and glycosaminoglycans research · Advanced Drug Delivery Systems · Cancer and biochemical research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Clinical Sciences, University of Nevada, Las Vegas—School of Dental Medicine, 1001 Shadow Lane, Las Vegas, NV 89106, USA

Department of Biomedical Sciences and Director of Student Research, University of Nevada, Las Vegas—School of Dental Medicine, 1001 Shadow Lane, Las Vegas, NV 89106, USA

References (30)

Show source-provided references
1. Activated hyaluronan metabolism in the tumor matrix—Causes and consequences10.1016/j.matbio.2018.04.012 ↗
2. Provisional matrix: A role for versican and hyaluronan
3. Recent developments in hyaluronic acid-based nanomedicine for targeted cancer treatment10.1517/17425247.2016.1112374 ↗
4. Tirnitz-Parker, J.E. (2019). The Role of the Tumor Microenvironment in the Development and Progression of Hepatocellular Carcinoma. Hepatocellular Carcinoma, Codon Publications.10.15586/hepatocellularcarcinoma.2019 ↗
5. Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression10.1186/s12943-019-1018-y ↗
6. Physiochemical properties and application of hyaluronic acid: A systematic review10.1111/jocd.12237 ↗
7. New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: Reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy10.1080/21691401.2017.1397001 ↗
8. A guide to hyaluronan and related enzymes in breast cancer: Biological significance and diagnostic value10.1111/febs.14860 ↗
9. Nanosoldiers: A promising strategy to combat triple negative breast cancer10.1016/j.biopha.2018.11.122 ↗
10. Hyaluronic acid family in bladder cancer: Potential prognostic biomarkers and therapeutic targets10.1038/bjc.2017.318 ↗
11. Prognostic implications of stromal hyaluronic acid protein expression in resected oropharyngeal and oral cavity cancers10.3904/kjim.2018.203 ↗
12. Serum hyaluronan levels in oral cancer patients10.1097/00029330-200802020-00009 ↗
13. Reduced expression of hyaluronan is a strong indicator of poor survival in oral squamous cell carcinoma10.1016/j.oraloncology.2003.08.004 ↗
14. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors10.1002/ijc.11252 ↗
15. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment10.1016/j.colsurfb.2018.09.076 ↗
16. Caution Should be Used in Long-Term Treatment with Oral Compounds of Hyaluronic Acid in Patients with a History of Cancer10.1007/s40261-015-0339-x ↗
17. Hyaluronic acid–paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism10.1016/j.oraloncology.2011.07.029 ↗
18. Hyaluronan-CD44 Promotes Phospholipase C–Mediated Ca2+ Signaling and Cisplatin Resistance in Head and Neck Cancer10.1001/archotol.132.1.19 ↗
19. Synergy between Intraperitoneal Aerosolization (PIPAC) and Cancer Nanomedicine: Cisplatin-Loaded Polyarginine-Hyaluronic Acid Nanocarriers Efficiently Eradicate Peritoneal Metastasis of Advanced Human Ovarian Cancer
20. Hyaluronic Acid-Modified Au-Ag Alloy Nanoparticles for Radiation/Nanozyme/Ag+ Multimodal Synergistically Enhanced Cancer Therapy10.1021/acs.bioconjchem.0c00224 ↗
21. Bioengineered scaffolds for 3D culture demonstrate extracellular matrix-mediated mechanisms of chemotherapy resistance in glioblastoma10.1016/j.matbio.2019.04.003 ↗
22. Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer10.1007/s10637-019-00740-4 ↗
23. Palumbo, A., Da Costa, N.M., Pontes, B., Oliveira, F.L., Codeço, M.L., Pinto, L.F.R., and Nasciutti, L.E. (2020). Esophageal Cancer Development: Crucial Clues Arising from the Extracellular Matrix. Cells, 9.10.3390/cells9020455 ↗
24. Hyaluronan preconditioning of monocytes/macrophages affects their angiogenic behavior and regulation of TSG-6 expression in a tumor type-specific manner10.1111/febs.14871 ↗
25. A facile approach for fabricating CD44-targeted delivery of hyaluronic acid-functionalized PCL nanoparticles in urethane-induced lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers10.1007/s13346-018-0575-8 ↗
26. Role of CD44 in tumor-initiating cells of salivary gland pleomorphic adenoma: More than a surface biomarker10.1111/odi.13279 ↗
27. Role of receptor for hyaluronan-mediated motility (RHAMM) in human head and neck cancers10.1007/s00432-014-1653-z ↗
28. Jung, S., Jung, S., Kim, D.-M., Lim, S.-H., Shim, Y.-H., Kwon, H., Kim, D.H., Lee, C.-M., Kim, B.-H., and Jeong, Y.-I. (2019). Hyaluronic Acid-Conjugated with Hyperbranched Chlorin e6 Using Disulfide Linkage and Its Nanophotosensitizer for Enhanced Photodynamic Therapy of Cancer Cells. Materials, 12.10.3390/ma12193080 ↗
29. Intracellular NO-Releasing Hyaluronic Acid-Based Nanocarriers: A Potential Chemosensitizing Agent for Cancer Chemotherapy10.1021/acsami.8b06848 ↗
30. Hyaluronic Acid in Inflammation and Tissue Regeneration